Hematology Oncology, P.C.
Stamford, Connecticut, United States
Hematologist in Stamford, Connecticut
34 Shelburne Rd, Stamford, CT 06902
About Hematology Oncology, P.C.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Genentech, Inc.
3
Bristol-Myers Squibb
2
Celgene
2
Incyte Corporation
2
Morphotek
2
Novartis Pharmaceuticals
2
Puma Biotechnology, Inc.
2
Synta Pharmaceuticals Corp.
2
Accelerated Community Oncology Research Network
1
CTI BioPharma
1
Celgene Corporation
1
Clinical Trials at Hematology Oncology, P.C.
During the past decade, Hematology Oncology, P.C. conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 7 clinical trials were completed, i.e. on
average, 350% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
1999-05-01
2012-08-01
Completed
19,747
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
2001-10-29
2009-02-10
Completed
569
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
2003-01-01
2004-10-01
Terminated
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
2003-06-01
2006-12-01
Completed
440
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
2003-04-18
2011-04-21
Completed
1,886
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
2004-08-01
2005-08-01
Completed
5,000
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2005-01-01
2007-09-01
Completed
131
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Hematology Oncology, P.C." #1 sponsor was "Genentech, Inc." with 3 trials, followed by "Bristol-Myers Squibb" with 2 trials
sponsored, "Celgene" with 2 trials sponsored, "Incyte Corporation" with 2 trials sponsored and "Morphotek"
with 2 trials sponsored. Other sponsors include 17 different institutions and
companies that sponsored additional 24 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology Oncology, P.C."
#1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 9 trials.
Clinical Trials Conditions at Hematology Oncology, P.C.
According to Clinical.Site data, the most researched conditions in "Hematology Oncology, P.C." are
"Breast Cancer" (4 trials), "Melanoma" (3 trials), "Multiple Myeloma" (3 trials), "Lung Cancer" (2 trials) and "Myelofibrosis" (2 trials). Many other conditions were trialed in "Hematology Oncology, P.C." in a lesser frequency.
Clinical Trials Intervention Types at Hematology Oncology, P.C.
Most popular intervention types in "Hematology Oncology, P.C." are "Drug" (30 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Paclitaxel" (4 trials), "Placebo" (4 trials), "Gemcitabine" (3 trials), "placebo" (3 trials) and "Capecitabine" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Hematology Oncology, P.C.
The vast majority of trials in "Hematology Oncology, P.C." are
26 trials for "All" genders and 7 trials for "Female" genders.
Clinical Trials Status at Hematology Oncology, P.C.
Currently, there are NaN active trials in "Hematology Oncology, P.C.".
undefined are not yet recruiting,
1 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 24 completed trials in Hematology Oncology, P.C.,
undefined suspended trials,
and 5 terminated clinical trials to date.
Out of the total trials that were conducted in Hematology Oncology, P.C., 2 "Phase 1"
clinical trials were conducted, 11 "Phase 2" clinical
trials and 17 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 0 trials that are defined as “Not Applicable".